Special Research Coverage Episodes

This week, I'm revisiting the proposal from the International Advisory Committee on Clinical Trials in MS that recommended adopting a new framework that leverages what scientists are continuing to learn about MS and redefines how we talk about MS, how we research MS, how we diagnose MS, and how we treat MS. This proposed framework holds the promise of taking MS care to the next level. This new framework was first proposed in a paper published in November 2022, and last January, I spoke with the...

The holiday season provides me with an opportunity to indulge in what's become a RealTalk MS tradition. I reserve the last two episodes of the year to revisit the most compelling,and important conversations that I've had over the past year. This week, I'm revisiting the conversations I had at the Pathways To Cures Global Summit that took place in New York last May. The National MS Society brought together the best and brightest minds in MS research, the CEOs of major MS Societies, representativ...

This special episode of RealTalk MS is sponsored by EMD Serono and is only intended for a U.S. audience. EMD Serono is the healthcare business of Merck, KGaA, Darmstadt, Germany, in the United States and Canada. In this special episode of RealTalk MS, we're exploring what the invisible symptoms of MS are, and how to best empower people living with MS to talk about them with their healthcare team. Professor Klaus Schmierer is a Professor of Neurology at the Blizard Institute, Queen Mary's Unive...

With more than 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Robert Motl. Dr. Motl is a professor in the department of Kinesiology and Nutrition, and a professor in the department o...

With more than 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Daniel Ontaneda. Dr. Ontaneda is a neurologist at the Cleveland Clinic Neurological Institute's Mellen Center for Multip...

With more than 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Annette Langer-Gould. Dr. Langer-Gould is an MS Specialist at Kaiser-Permanente, and while at the ECTRIMS-ACTRIMS meetin...

With more than 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Anthony Feinstein. Dr. Feinstein is a Professor of Psychiatry at the University of Toronto, and his expertise is in the ...

This week, we're sharing more from the 2023 joint ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) and ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) annual meeting. What if we could identify MS before anyone experienced any of the typical clinical symptoms? Would treating that person with a high-efficacy disease-modifying therapy prevent the clinical symptoms of MS from even developing? Those are the questions that make the study of t...

With about 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Jiwon Oh. Dr. Oh is a neurologist, scientist, and the Medical Director of the Barlo Multiple Sclerosis Program at St. Michae...

Last week, more than 9,000 MS research scientists and clinicians from more than 110 countries traveled to Milan to attend the largest MS research conference in the world, the 2023 joint ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) and ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) annual meeting. In keeping with a RealTalk MS tradition, just as the meeting was ending and the thousands of attendees were heading for the exits, I conn...